Acute and Chronic Effects of Angiotensin Converting Enzyme Inhibitors on the Essential Hypertensive Kidney

Overview

Journal Cardiovasc Drugs Ther

Specialties Cardiology & Vascular Diseases
Pharmacology

Date 1990 Feb 1

PMID 2285613

Authors

G P Reams

J H Bauer

Affiliations

Soon will be listed here.

Abstract

The natural course of essential hypertensive renal disease is characterized by a slowly progressive impairment of renal function. Initially, the changes are functional and reversible; however, structural changes gradually occur, leading to hypertensive nephrosclerosis. Similarities exist between the early functional hemodynamic changes observed in the essential hypertensive kidney and the physiologic renal effects of angiotensin II. To the degree that the initial functional changes are the result of excessive endogenous production of angiotensin II, interruption of the integrity of this humoral system could be expected to reverse the pathophysiologic sequence of events leading to hypertensive nephrosclerosis. This review focuses on the pathophysiology of the essential hypertensive kidney, the intrarenal effects of angiotensin II, and the acute and chronic effects of angiotensin converting enzyme (ACE) inhibition therapy on the essential hypertensive kidney. The data reviewed suggest that ACE inhibition therapy does reverse the initial functional hemodynamic changes observed in the essential hypertensive kidney and may protect the glomerulus from hemodynamically mediated injury.

References

Faubert P, CHOU S, Porush J . Regulation of papillary plasma flow by angiotensin II. Kidney Int. 1987; 32(4):472-8. DOI: 10.1038/ki.1987.234. View

Wenting G, Derkx F, de Bruyn J, Man int Veld A, SCHALEKAMP M . Splint renal function after captopril in unilateral renal artery stenosis. Br Med J (Clin Res Ed). 1984; 288(6421):886-90. PMC: 1441698. DOI: 10.1136/bmj.288.6421.886. View

Hollenberg N, Adams D, Solomon H, Chenitz W, Burger B, ABRAMS H . Renal vascular tone in essential and secondary hypertension: hemodynamic and angiographic responses to vasodilators. Medicine (Baltimore). 1975; 54(1):29-44. DOI: 10.1097/00005792-197501000-00002. View

Unger T, Schull B, Rascher W, Lang R, Ganten D . Selective activation of the converting enzyme inhibitor MK 421 and comparison of its active diacid form with captopril in different tissues of the rat. Biochem Pharmacol. 1982; 31(19):3063-70. DOI: 10.1016/0006-2952(82)90081-8. View

Kastner P, Hall J, GUYTON A . Control of glomerular filtration rate: role of intrarenally formed angiotensin II. Am J Physiol. 1984; 246(6 Pt 2):F897-906. DOI: 10.1152/ajprenal.1984.246.6.F897. View

Castleman B, SMITHWICK R . The relation of vascular disease to the hypertensive state; the adequacy of the renal biopsy as determined from a study of 500 patients. N Engl J Med. 1948; 239(20):729-32. DOI: 10.1056/NEJM194811112392001. View

Romero J, KNOX F . Mechanisms underlying pressure-related natriuresis: the role of the renin-angiotensin and prostaglandin systems. State of the art lecture. Hypertension. 1988; 11(6 Pt 2):724-38. DOI: 10.1161/01.hyp.11.6.724. View

Lewis E . Proteinuria and abnormalities of the renal glomerulus in patients with hypertension. Clin Exp Pharmacol Physiol Suppl. 1982; 7:105-15. View

Shionoiri H, Yasuda G, Takagi N, Oda H, Young S, Miyajima E . Renal haemodynamics and comparative effects of captopril in patients with benign- or malignant-essential hypertension, or with chronic renal failure. Clin Exp Hypertens A. 1987; 9(2-3):543-9. DOI: 10.3109/10641968709164222. View

10.

Blantz R, Pelayo J . In vivo actions of angiotensin II on glomerular function. Fed Proc. 1983; 42(14):3071-4. View

11.

Bauer J, Jones L . Comparative studies: enalapril versus hydrochlorothiazide as first-step therapy for the treatment of primary hypertension. Am J Kidney Dis. 1984; 4(1):55-62. DOI: 10.1016/s0272-6386(84)80027-x. View

12.

CHASIS H, REDISH J . EFFECTIVE RENAL BLOOD FLOW IN THE SEPARATE KIDNEYS OF SUBJECTS WITH ESSENTIAL HYPERTENSION. J Clin Invest. 1941; 20(6):655-61. PMC: 435095. DOI: 10.1172/JCI101258. View

13.

Ljungman S, Aurell M, Hartford M, Wikstrand J, Wilhelmsen L, Berglund G . Blood pressure and renal function. Acta Med Scand. 1980; 208(1-2):17-25. DOI: 10.1111/j.0954-6820.1980.tb01144.x. View

14.

Ingelfinger J, PRATT R, Ellison K, Dzau V . Sodium regulation of angiotensinogen mRNA expression in rat kidney cortex and medulla. J Clin Invest. 1986; 78(5):1311-5. PMC: 423820. DOI: 10.1172/JCI112716. View

15.

GOLDRING W, CHASIS H, RANGES H, Smith H . EFFECTIVE RENAL BLOOD FLOW IN SUBJECTS WITH ESSENTIAL HYPERTENSION. J Clin Invest. 1941; 20(6):637-53. PMC: 435094. DOI: 10.1172/JCI101257. View

16.

Johnston C, Millar J, McGrath B, Matthews P . Long-term effects of captopril (SQ14 225) on blood-pressure and hormone levels in essential hypertension. Lancet. 1979; 2(8141):493-6. DOI: 10.1016/s0140-6736(79)91552-6. View

17.

Hall J . Control of sodium excretion by angiotensin II: intrarenal mechanisms and blood pressure regulation. Am J Physiol. 1986; 250(6 Pt 2):R960-72. DOI: 10.1152/ajpregu.1986.250.6.R960. View

18.

Schuster V, Kokko J, Jacobson H . Angiotensin II directly stimulates sodium transport in rabbit proximal convoluted tubules. J Clin Invest. 1984; 73(2):507-15. PMC: 425042. DOI: 10.1172/JCI111237. View

19.

Unger T, Ganten D, Lang R, Scholkens B . Persistent tissue converting enzyme inhibition following chronic treatment with Hoe498 and MK421 in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1985; 7(1):36-41. DOI: 10.1097/00005344-198501000-00007. View

20.

Curtis J, Luke R, Whelchel J, Diethelm A, Jones P, DUSTAN H . Inhibition of angiotensin-converting enzyme in renal-transplant recipients with hypertension. N Engl J Med. 1983; 308(7):377-81. DOI: 10.1056/NEJM198302173080707. View